{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:34:07Z","timestamp":1786984447954,"version":"build-2736575974"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.anl.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:35:06Z","timestamp":1761042906000},"page":"709-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Summary of Japanese clinical practice guidelines for head and neck cancer - 2025 update edited by the Japan Society for Head and Neck Cancer"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2524-8283","authenticated-orcid":false,"given":"Nobuhiro","family":"Hanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-2545","authenticated-orcid":false,"given":"Mizuo","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ishiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-4047","authenticated-orcid":false,"given":"Nobuhiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-1137","authenticated-orcid":false,"given":"Isaku","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-831X","authenticated-orcid":false,"given":"Hiroyuki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-5332","authenticated-orcid":false,"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-7783","authenticated-orcid":false,"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shinomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fuseya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-4493","authenticated-orcid":false,"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-3051","authenticated-orcid":false,"given":"Koichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Nibu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-095X","authenticated-orcid":false,"given":"Seiichi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-0646","authenticated-orcid":false,"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2025.09.004_bib0001","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00405-009-1166-6","article-title":"The impact of paratracheal lymph node metastasis in squamous cell carcinoma of the hypopharynx","volume":"267","author":"Joo","year":"2010","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.anl.2025.09.004_bib0002","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jjco\/hyz019","article-title":"Surgical management around the paratracheal area of hypopharyngeal cancer","volume":"49","author":"Tomioka","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.anl.2025.09.004_bib0003","first-page":"E1969","article-title":"Pattern of lymph node metastasis in hypopharyngeal squamous cell carcinoma and indications for level VI lymph node dissection","volume":"38","author":"Chung","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0004","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/lary.24299","article-title":"Pattern of cervical lymph node metastasis in medial wall pyriform sinus carcinoma","volume":"124","author":"Chung","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2025.09.004_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2468\/jbes.73.8","article-title":"Paratracheal lymph node dissection during laryngectomy for pyriform sinus carcinoma of the hypopharynx","volume":"73","author":"Miyabe","year":"2022","journal-title":"J Jpn Bronchoesophagol Soc"},{"key":"10.1016\/j.anl.2025.09.004_bib0006","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hed.27572","article-title":"Extent of thyroidectomy and paratracheal lymph node dissection in total pharyngolaryngectomy for pyriform sinus cancer, and recurrence, survival, and postoperative hypoparathyroidism: a multicenter retrospective study","volume":"46","author":"Ariizumi","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0007","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/j.1531-4995.1979.tb00109.x","article-title":"Stomal recurrences: a clinicopathological analysis and protocol for future management","volume":"89","author":"Myers","year":"1979","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2025.09.004_bib0008","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcms.2008.12.006","article-title":"Post-laryngectomy stomal cancer recurrences, re-treatment decisions and outcomes: case series","volume":"37","author":"Ampil","year":"2009","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.anl.2025.09.004_bib0009","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1288\/00005537-198709000-00005","article-title":"Surgical salvage for stomal recurrence: a multi-institutional experience","volume":"97","author":"Gluckman","year":"1987","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2025.09.004_bib0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2468\/jbes.71.397","article-title":"Postoperative parathyroid function in patients with hypopharyngeal carcinoma undergoing total pharyngolaryngectomy","volume":"71","author":"Takahashi","year":"2020","journal-title":"J Jpn Bronchoesophagol Soc"},{"key":"10.1016\/j.anl.2025.09.004_bib0011","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10147-014-0709-z","article-title":"Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study","volume":"20","author":"Omura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0012","first-page":"91","article-title":"Preservation of parathyroid function in total pharyngolaryngectomy for hypopharyngeal carcinoma","volume":"16","author":"Yokoshima","year":"2006","journal-title":"Jpn J Head Neck Surg"},{"key":"10.1016\/j.anl.2025.09.004_bib0013","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bjps.2007.09.030","article-title":"Fasciocutaneous free flaps in pharyngolaryngo-oesophageal reconstruction: a critical review of the literature","volume":"61","author":"Murray","year":"2008","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.anl.2025.09.004_bib0014","first-page":"486","article-title":"Multicenter study of reconstruction after pharyngolaryngoesophagectomy","volume":"32","author":"Sugiyama","year":"2006","journal-title":"Jpn J Head Neck Cancer"},{"key":"10.1016\/j.anl.2025.09.004_bib0015","doi-asserted-by":"crossref","first-page":"e1599","DOI":"10.1097\/GOX.0000000000001599","article-title":"Efficacy of tensed and straight free jejunum transfer for the reduction of postoperative dysphagia","volume":"28","author":"Tachibana","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.anl.2025.09.004_bib0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/02844319850158651","article-title":"Comparative evaluation in pharyngo-oesophageal reconstruction: radial forearm flap compared with jejunal flap. A 10-year experience","volume":"32","author":"Nakatsuka","year":"1998","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"key":"10.1016\/j.anl.2025.09.004_bib0017","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00595-008-4050-x","article-title":"Free jejunal graft reconstruction after resection of neck cancers: our surgical technique","volume":"39","author":"Ikeguchi","year":"2009","journal-title":"Surg Today"},{"key":"10.1016\/j.anl.2025.09.004_bib0018","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/hed.27526","article-title":"Long-term surgical and functional outcomes after anterolateral thigh flap and free jejunal transfer reconstruction of circumferential pharyngoesophageal defects","volume":"45","author":"Ishida","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105809","article-title":"Circumferential pharyngeal reconstruction after total laryngopharyngectomy: a systematic review and network meta-analysis","volume":"127","author":"Costantino","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hed.21169","article-title":"Circumferential pharyngeal reconstruction: history, critical analysis of techniques, and current therapeutic recommendations","volume":"32","author":"Patel","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0021","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00405-014-3306-x","article-title":"Hypopharyngeal reconstruction: a comparison of three alternatives","volume":"272","author":"Elfeky","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.anl.2025.09.004_bib0022","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1442-2050.2007.00781.x","article-title":"Comparison of free jejunal graft with gastric pull-up reconstruction after resection of hypopharyngeal and cervical esophageal carcinoma","volume":"21","author":"Ferahkose","year":"2008","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.anl.2025.09.004_bib0023","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hed.10233","article-title":"Speech and swallowing outcomes in reconstructions of the pharynx and cervical esophagus","volume":"25","author":"Robb","year":"2003","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0024","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.anl.2016.03.011","article-title":"Late-onset dysphagia caused by severe spastic peristalsis of a free jejunal graft in a case of hypopharyngeal cancer","volume":"43","author":"Imai","year":"2016","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.anl.2025.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hed.25139","article-title":"Postoperative mechanical bowel obstruction after pharyngolaryngectomy for hypopharyngeal cancer: retrospective analysis using a Japanese inpatient database","volume":"40","author":"Suzuki","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0026","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anl.2025.09.004_bib0027","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3390\/cancers12082104","article-title":"Novel targeted therapies for metastatic thyroid cancer: a comprehensive review","volume":"12","author":"Al-Jundi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.anl.2025.09.004_bib0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2025.09.004_bib0029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2025.09.004_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2025.09.004_bib0031","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0032","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2025.09.004_bib0033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0034","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF V600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0036","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancer","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2025.09.004_bib0037","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fonc.2017.00238","article-title":"Targeted therapy for medullary thyroid cancer: a review","volume":"7","author":"Priya","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0038","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Jr","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0039","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1089\/thy.2016.0621","article-title":"Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma","volume":"27","author":"Ito","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0041","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon-2018-0557","article-title":"A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer","volume":"15","author":"Takahashi","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0042","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2025.09.004_bib0043","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.anl.2025.09.004_bib0044","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/thy.2000.10.587","article-title":"Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group","volume":"10","author":"Ain","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/thy.2013.0078","article-title":"Randomized safety and efficacy study of fosbretabulin with paclitaxel\/carboplatin against anaplastic thyroid carcinoma","volume":"24","author":"Sosa","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0046","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/thy.2016.0072","article-title":"The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study","volume":"26","author":"Onoda","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0047","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/cancers11070943","article-title":"A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer","volume":"11","author":"Ljubas","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.anl.2025.09.004_bib0048","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0049","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0051","first-page":"1184","article-title":"Dabrafenib versus dabrafenib plus trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0052","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.anl.2025.09.004_bib0053","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.anl.2025.09.004_bib0054","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"LIBRETTO-531 trial investigators. Phase 3 trial of Selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2025.09.004_bib0055","first-page":"1","article-title":"Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer","volume":"7","author":"Debaere","year":"2011","journal-title":"B-ENT"},{"key":"10.1016\/j.anl.2025.09.004_bib0056","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2025.09.004_bib0057","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hed.24933","article-title":"Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and\/or metastatic salivary gland cancer of the head and neck","volume":"40","author":"Hong","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0058","doi-asserted-by":"crossref","first-page":"843","DOI":"10.21873\/invivo.11549","article-title":"Carboplatin and docetaxel in patients with salivary gland carcinoma: a retrospective study","volume":"33","author":"Okada","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.anl.2025.09.004_bib0059","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12032-021-01581-z","article-title":"Docetaxel plus cisplatin in recurrent and\/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial","volume":"38","author":"Imamura","year":"2021","journal-title":"Med Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4143\/crt.2021.1019","article-title":"A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.anl.2025.09.004_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1185198","article-title":"Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin","volume":"13","author":"Onaga","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0062","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfister","year":"2007","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0063","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bjoms.2010.09.013","article-title":"Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma","volume":"49","author":"Ghosal","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.anl.2025.09.004_bib0064","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0066","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.anl.2025.09.004_bib0067","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0068","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0069","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2025.09.004_bib0070","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.anl.2025.09.004_bib0071","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0072","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0073","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.32754","article-title":"Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life","volume":"126","author":"Locati","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.anl.2025.09.004_bib0074","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2025.09.004_bib0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0076","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0077","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-24-0455","article-title":"Apalutamide and goserelin for androgen receptor-positive salivary gland carcinoma: a phase II nonrandomized clinical trial, YATAGARASU","volume":"30","author":"Honma","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2025.09.004_bib0078","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0079","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0081","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: a phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0082","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73965-6","article-title":"Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma","volume":"10","author":"Niwa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.anl.2025.09.004_bib0083","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0084","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70779-8","article-title":"PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab","volume":"14","author":"Matsuki","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.anl.2025.09.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132476","article-title":"The Harmonic Scalpel versus conventional hemostasis for neck dissection: a meta-analysis of the randomized controlled trials","volume":"10","author":"Ren","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.anl.2025.09.004_bib0086","doi-asserted-by":"crossref","first-page":"e702","DOI":"10.1055\/s-0044-1779010","article-title":"Neck dissection with harmonic instruments and electrocautery: a systematic review","volume":"28","author":"Dedivitis","year":"2024","journal-title":"Int Arch Otorhinolaryngol"},{"key":"10.1016\/j.anl.2025.09.004_bib0087","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1007\/s00405-021-06739-z","article-title":"A comparison of the Thunderbeat and standard electrocautery devices in head and neck surgery: a prospective randomized controlled trial","volume":"278","author":"Kuipers","year":"2021","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.anl.2025.09.004_bib0088","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/coa.12702","article-title":"A prospective randomised trial of LigaSure Small Jaw\u00ae versus conventional neck dissection in head and neck cancer patients","volume":"42","author":"Lin","year":"2017","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.anl.2025.09.004_bib0089","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.oraloncology.2016.08.010","article-title":"Comparison of spinal accessory dysfunction following neck dissection with harmonic scalpel and electrocautery - A randomized study","volume":"61","author":"Mathialagan","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1758-3284-1-21","article-title":"Ultrasonic partial glossectomy","volume":"1","author":"Pons","year":"2009","journal-title":"Head Neck Oncol"},{"key":"10.1016\/j.anl.2025.09.004_bib0091","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hed.20202","article-title":"Ultrasonic glossectomy: simple and bloodless","volume":"27","author":"Yuen","year":"2005","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0092","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00106-001-0596-2","article-title":"The \"Ultracision Harmonic scalpel\" ultrasound activated scalpel. Initial results in surgery of the tongue and soft palate","volume":"50","author":"Metternich","year":"2002","journal-title":"HNO"},{"key":"10.1016\/j.anl.2025.09.004_bib0093","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2025.09.004_bib0094","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s10147-021-01960-6","article-title":"A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma","volume":"26","author":"Tahara","year":"2021","journal-title":"Int J Clin Oncol"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814625001403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814625001403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:09:36Z","timestamp":1773295776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814625001403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0385814625001403"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2025.09.004","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Summary of Japanese clinical practice guidelines for head and neck cancer - 2025 update edited by the Japan Society for Head and Neck Cancer","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}